Table 2.
A list of clinical trials involving carrageenan for the common cold and SARS-CoV-2 infection that have been registered on ClinicalTrials.gov.
| Identifier number | Title | Intervention | Status | Phase | Location |
|---|---|---|---|---|---|
| NCT01944631 | Iota-carrageenan nasal spray in common cold | Four times daily for 4–10 days, nasal spray containing 1.20 g/l iota-carrageenan in saline | completed | 4 | UK |
| NCT04533906 | Study to Investigate if Sucking a Coldamaris Lozenge Elutes Sufficient Iota-carrageenan to Inactivate Usual Common Cold Viruses | Sucking iota-carrageenan containing lozenge | completed | NA | Austria |
| NCT04425850 | Usefulness of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19 (IVERCAR) | Ivermectin nasal spray and Iota carrageenan nasal spray (used as buccal drops 5 times a day). Application to the nose and oral cavity on a topical basis. | completed | NA | Argentina |
| NCT04701710 | Prophylaxis Covid-19 in healthcare agents by intensive treatment with ivermectin and iota-carrageenan (Ivercar-Tuc) | Ivermectin 2 drops of 6 mg equals 12 mg every 7 days orally, and iota-carrageenan 6 sprays daily for 4 weeks | completed | 2 | Argentina |
| NCT04793984 | Efficacy and Safety Evaluation of Inhaleen Inhalation in Hospitalized COVID-19 Patients | Inhalation of Carragelose® (contains 1.2 mg/ml iota-carrageenan) three times daily | recruiting | – | Austria |
| NCT04681001 | Prophylactic treatment with carragelose nasal spray to prevent SARS-CoV-2, COVID-19, infections in health care workers | Nasal spray of Coldamaris pro. (contains 1.2 mg/ml iota-carrageenan) into nostrils and mouth | recruiting | – | Austria |
| NCT04590365 | Iota-carrageenan nasal spray COVID-19 prophylaxis for healthcare professionals (ICE-COVID) | Coldamaris plus nasal and throat spray (Iota-carrageenan 0.12% in 0.5% saline) | recruiting | – | UK |